Clinical-stage Metsera has emerged from stealth with $290 million in hand and the bold vision of ushering in the next generation of obesity and metabolic disease medicines. | Clinical-stage Metsera has emerged from stealth with $290 million in hand and the bold vision of ushering in the next generation of obesity and metabolic disease medicines.
Sage Therapeutics has set a bad PRECEDENT for dalzanemdor. | Sage Therapeutics has set a bad PRECEDENT for dalzanemdor. The therapy failed to improve cognitive ability in a phase 2 Parkinson’s disease study, setting Sage off on the wrong foot at the start of a sequence of readouts that will define the future of the molecule.